ArticleClinical pharmacology and therapeutics2013
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Article in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Human papillomavirus and lung cancer: an overview and a meta-analysis.Journal of cancer research and clinical oncology · 2019Pooled it
- The genetic vulnerability to cisplatin ototoxicity: a systematic review.Scientific reports · 2019Pooled it
- TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Pharmacogenetics and genomics · 2017Pooled it
- Platinum-induced hearing loss after treatment for childhood cancer.The Cochrane database of systematic reviews · 2016Pooled it
- Pooled it
- Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.Clinical pharmacology and therapeutics · 2026Review
- Article
- The Role of Genetic and Non-Genetic Factors in the Occurrence of Cisplatin-Associated Ototoxicity.International journal of molecular sciences · 2025Review
- Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population.Frontiers in pharmacology · 2025Article
- Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy.International journal of molecular sciences · 2023Article
- Modern developments in germline pharmacogenomics for oncology prescribing.CA: a cancer journal for clinicians · 2022Review
- TPMT mRNA Expression: A Novel Prognostic Biomarker for Patients with Colon Cancer by Bioinformatics Analysis.International journal of general medicine · 2022Article
- Pharmacogenomics in Children.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation.Advanced drug delivery reviews · 2021Review
- The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.International journal of molecular sciences · 2020Review
- Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.The pharmacogenomics journal · 2020Article
- Influence of Genetic Variation inGenes · 2020Article
- Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.The Journal of molecular diagnostics : JMD · 2019Article
- Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.JMIR research protocols · 2019Article
- Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors at 1 institution in 2 countries.
Funding
Abstract
Ototoxicity is a debilitating side effect of platinating agents with substantial interpatient variability. We sought to evaluate the association of thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) genetic variations with cisplatin-related hearing damage in the context of frontline pediatric cancer treatment protocols. In 213 children from the St. Jude Medulloblastoma-96 and -03 protocols, hearing loss was related to younger age (P = 0.013) and craniospinal irradiation (P = 0.001), but did not differ by TPMT or COMT variants. Results were similar in an independent cohort of 41 children from solid-tumor frontline protocols. Functional hearing loss or hair cell damage was not different in TPMT knockout vs. wild-type mice following cisplatin treatment, and neither TPMT nor COMT variant was associated with cisplatin cytotoxicity in lymphoblastoid cell lines. In conclusion, our results indicated that TPMT or COMT genetic variation was not related to cisplatin ototoxicity in children with cancer and did not influence cisplatin-induced hearing damage in laboratory models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.